文献速递类风湿关节炎

类风湿关节炎患者接受JAK抑制剂治疗的不良心血管事件:上市后自发安全性报告分析

Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports.
PubMed 文献 · Semin Arthritis Rheum · 2024-05-17

基于FAERS数据库的回顾性药物警戒研究,分析2015年1月至2023年6月类风湿关节炎患者使用JAK抑制剂的心血管不良事件报告。与bDMARDs相比,JAK抑制剂与静脉血栓栓塞、卒中、缺血性心脏病、外周水肿和快速性心律失常的报告增加相关,多数事件发生在治疗起始后第一年,提示类效应。

要点

  • 与bDMARDs相比,JAK抑制剂与静脉血栓栓塞报告增加相关(adj.ROR=2.11)。
  • JAK抑制剂与卒中、缺血性心脏病、外周水肿和快速性心律失常报告增加相关。
  • 多数事件发生在治疗起始后第一年,乌帕替尼和巴瑞替尼的静脉血栓栓塞、卒中、缺血性心脏病报告频率高于托法替布。

核心结论

  • 在这项全球上市后研究中,JAK抑制剂与静脉血栓栓塞、卒中、缺血性心脏病和快速性心律失常的报告增加相关。
  • 这些不良事件在所有被研究的JAK抑制剂中均有报告,提示类效应。

研究设计与样本

  • 回顾性药物警戒研究,使用FDA不良事件报告系统(FAERS),评估2015年1月至2023年6月类风湿关节炎患者接受JAK抑制剂治疗后的不良心血管事件报告。
  • 采用多变量逻辑回归模型计算校正报告比值比(adj.ROR)以识别报告不成比例增加。
  • 识别JAK抑制剂治疗类风湿关节炎患者安全性报告75,407例(托法替布n=52,181;乌帕替尼n=21,006;巴瑞替尼n=2,220),bDMARDs治疗患者303,278例(TNF抑制剂、利妥昔单抗和托珠单抗)。
  • JAK抑制剂组平均年龄61.2(±12)岁,女性占82%;bDMARDs组平均年龄59.0(±13)岁,女性占81%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The ORAL Surveillance trial, a postmarketing safety clinical trial, found an increased risk of adverse cardiovascular events and venous thromboembolism (VTE) in patients treated with Janus Kinase (JAK) inhibitors compared to tumor necrosis factor (TNF) inhibitors. However, additional studies yielded mixed results and data on other JAK inhibitors are limited. METHODS: A retrospective, pharmacovigilance study using the FDA adverse event reporting system (FAERS) to assess reporting of adverse cardiovascular events following treatment with JAK inhibitors in rheumatoid arthritis (RA) patients between January 2015 and June 2023. To identify disproportionately increased reporting, an adjusted reporting odds ratio (adj.ROR) was calculated with a multivariable logistic regression model. RESULTS: We identified safety reports of 75,407 RA patients treated with JAK inhibitors (tofacitinib, n = 52,181; upadacitinib, n = 21,006; baricitinib, n = 2,220) and 303,278 patients treated with biologic disease-modifying antirheumatic drugs (bDMARDs; TNF inhibitors, rituximab, and tocilizumab). The mean age was 61.2(±12) and 59.0(±13), respectively; 82 % and 81 % were women. Compared to bDMARDs, JAK inhibitors were associated with an increased reporting of VTE [n = 1,393, adj.ROR=2.11 (1.97-2.25)], stroke [n = 973, adj.ROR=1.25 (1.16-1.34)], ischemic heart disease [IHD, n = 999, adj.ROR=1.23 (1.13-1.33)], peripheral edema [n = 2699, adj.ROR=1.22 (1.17-1.28)], and tachyarrhythmias [n = 370, adj.ROR=1.15 (1.00-1.33)]. Most of the events occurred in the first year after treatment initiation. When different JAK inhibitors were compared, VTE, stroke, and IHD were more frequently reported with upadacitinib and baricitinib than tofacitinib. When stratified by age category, all safety signals were statistically significant in patients aged≤65 years. CONCLUSION: In this global postmarketing study, JAK inhibitors are associated with increased reporting of VTE, stroke, IHD, and tachyarrhythmias. These adverse events were reported following all JAK inhibitors that were studied, suggesting a class effect.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Goldman A, Galper BL, Druyan A, et al. Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports. Semin Arthritis Rheum. 2024. PMID: 38772185. doi:10.1016/j.semarthrit.2024.152461

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。